Effects on fatty liver: decomposed into diisopropylamine and dichloroacetic acid in the body, promoting choline synthesis, promoting liver fat decomposition; transporting liver fat, reducing fat accumulation in the liver. Effects on lipid metabolism: inhibit fat mobilization, cholesterol synthesis and fatty acid synthesis. Liver protection: improves the energy metabolism of liver cells, enhances liver cell membrane fluidity, increases Na-K-ATPase activity, promotes the repair of damaged liver cell function, improves tissue cell respiratory function and oxygen utilization, and accelerates fatty acid oxidation.

The specific pharmacological effects are not clearly mentioned.

Effect on fatty liver: decomposed into diisopropylamine and dichloroacetic acid in the body, promoting choline synthesis and consuming liver fat; Effect on lipid metabolism: inhibit fat mobilization, cholesterol synthesis and fatty acid synthesis; Liver protection effect: improve liver cell energy metabolism, enhance liver cell membrane fluidity, increase Na-K-ATPase activity, promote damaged liver cell function repair, and accelerate fatty acid oxidation.

Participates in energy metabolism and supports liver function recovery.

This product is a broad-spectrum antibacterial drug with strong antibacterial effects on both Gram-positive and Gram-negative bacteria. There is no cross-resistance between similar drugs and antibiotics. It has strong antibacterial activity against Gram-negative bacteria, especially bacteria of the Enterobacteriaceae family, such as Escherichia coli, Shigella, Klebsiella, Proteus, Enterobacter aerogenes, Serratia, Citrobacter, etc., which are highly sensitive to this product, and the minimum inhibitory concentration is generally less than 0.5mu;g/ml. It also has an effect on Pseudomonas aeruginosa and other Pseudomonas, but requires a higher concentration, with a minimum inhibitory concentration of 4 to 32mu;g/ml; because the concentration in urine exceeds the above concentration by several to more than ten times, it is still effective for the treatment of Pseudomonas aeruginosa urinary tract infections. Among Gram-positive cocci, it is more sensitive to Staphylococcus aureus and Staphylococcus epidermidis. The minimum concentration for inhibiting 90% of bacteria is about 1-2 mu;g/ml, and the minimum concentration for inhibiting 90% of enterococci and pneumococci is about 4 mu;g/ml and 16 mu;g/ml.

This product is a broad-spectrum antibacterial drug in the semi-synthetic rifamycin class. Its mechanism of action is to inhibit the activity of ribonucleic acid polymerase in bacteria, thereby affecting the synthesis of ribonucleic acid and protein metabolism, resulting in the cessation of bacterial growth and reproduction to achieve a bactericidal effect. The sensitive bacteria of this product include: Staphylococcus aureus (including penicillin-resistant and neomycin-resistant strains), Mycobacterium tuberculosis, Streptococcus pyogenes, Pneumococcus, Gonorrhea, Escherichia coli, Meningococcus, Haemophilus influenzae, Legionella, etc.

The results of in vitro tests showed that this product had an inhibitory effect on the growth of both gastric cancer cell lines 801 and 803; the results of in vivo animal tests showed that this product had a prolonging effect on the average survival time of tumor-bearing rats inoculated with W256 carcinosarcoma in the gastric muscle layer.